Skip to content

Effect of hydrogen-rich water on chronic obstructive pulmonary disease patients: A randomized, controlled, double-blind clinical trial

Effect of hydrogen-rich water on chronic obstructive pulmonary disease patients: A randomized, controlled, double-blind clinical trial - Effect of hydrogen-rich water on COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010459
Enrollment
70
Registered
2013-05-01
Start date
2013-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease: COPD

Interventions

Patients drink hydrogen-rich water 500ml/day for 1 year. Patients drink placebo water 500ml/day for 1 year.

Sponsors

Juntendo University, Faculty of Medicine
Lead Sponsor
MiZ Company Limited
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. FEV1/FVC < 0.7 and FEV1 < 80% predicted (Grade 2-4 of classification of severity in the GOLD guideline) 2. Patients who are complain of dyspnea continuously. 3. Patients who can perform pulmonary function test. 4. Patients without disturbance of swallowing. 5. Male and female patients aged 40 years or older with any smoking histories. 6. Patients who go to the outpatient clinic regularly. 7. Patients who can acquire a document agreement.

Exclusion criteria

Exclusion criteria: 1. Patients who is complicated with chronic respiratory disease except COPD. 2. Patients with disturbance of swallowing 3. Patients who cannot understand how to drink a sample safety. 4. Patients with severe comorbidities 5. Patients who receive treatments of severe diseases such as cancers 6. Patients who are pregnant and nursing, and hope to be pregnant. 7. Patients who has a past history of severe allergy. 8. In addition, patients who judged that the examination medical attendant was inappropriate.

Design outcomes

Primary

MeasureTime frame
The change of dyspnea scale, the CCQ score and the frequency of exacerbation

Secondary

MeasureTime frame
Pulmonary function test SGRQ and CAT score Oxidative and inflammatory markers

Countries

Japan

Contacts

Public ContactTadashi Sato

Juntendo University, Faculty of Medicine Department of Respiratory Medicine

satotada@juntendo.ac.jp03-5802-1063

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026